Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You will have a chance tomorrow morning to add at a cheaper price!
It would be awesome if we closed green. However I think since we broke the previous days low I would imagine a red close. Those who were coming into this week's trading carrying a sentiment of "this should be an exciting week." I doubt this is what they had in mind. If however we get the pullback I would imagine it would be short-lived with Epilepsy data out Friday. Monday actually is when we might see a PR. Close GREEN boys!
Yup there she went. Back down to where is the question?
Nope not today down she goes. Doesn't look to promising for our continuing of the uptrend.
I'm ok with this still going in the right direction here. We keep continuing with the higher highs and lower lows. Its good I believe until we break the previous days low.
Now many refrain from investing in Penny's but it has happened before and will happen again.
Let me just squash this right here. Mutual funds can buy whatever the hell there mutual guidelines interpret. I'm in this field specifically and I know many funds that do buy penny stocks. However some funds classify penny stocks under different categories. IE meaning under $5 some under $3 it's all up to the funds guidelines. PERIOD!!!
From what Dr. Missling told me this could be a therapy for many cognitive diseases. Parkinson's, Alzheimers, Epilepsy, etc... If in fact we show positives results with the phase II trial there will be big pharma's just throwing money our way. Should be exciting! Its an open label trial so Dr. Missling knows what is transpire with the patients. His words were "we are extremely excited."
Neither
Oh great question wasn't that specific I doubt this 10Q just because he told me the whole story behind the matter. If you can call it that.
Absolutely and remember what I said this is an open label trial!!! Patent issue is no issue and will be resolved by 10Q. I expect to be honest not his words but I expect we get some kind of bullish statement when he gives enrollment status this quarter.
Just got off phone with Dr. Missling and I'm very excited. Hard to understand with thick accent but wow good stuff.
.354 registered on Level II
All my questions have been answered and replied to in a timely fashion. In fact this is the first biotech that I have ever held where it is such. But go ahead give them a call or write an email and I'm sure they will respond in a swift matter. None of my questions have ever been dodged! PERIOD!
Here is your answer from IR as to who is the biggest institutional investors:
Thanks for the clarification. I will look forward to receiving your phone number so that I can ask management to give you a call.
In the meantime, Anavex’s largest institutional investors are Sphera, Auriga, DAFNA and Sabby.
Please do not hesitate to contact our office if we can be of further assistance.
On behalf of Anavex Life Sciences Corp.,
After reviewing further about the trial and the primary endpoint along with secondary endpoints I realized that this is an open-label study. So if I'm correct won't the Docs know well before Sept if the drug is a success? I mean we could hear some very bullish statements from Dr. Missling from now until then and it could be sign of things to come, right?
I find this a little weird that today's volume has all but dried up? Any comments?
That wasn't my point. I merely said that we are far to early to make any kind of judgements on the success of any trial. We are at pre-clinical levels a lot can go wrong from now until human trials. Just because we show positive pre-clinical results doesn't mean in anyway that human trials will have the same success. That is what I know to be a fact. But good luck!
I know one thing for sure cause I have been on the wrong side of it more often than not but a lot of phase II trials fail due to the trial design. So can anyone comment on Anavex and there adaptive trial design? Endpoints and secondary endpoints?
No offense but I somehow don't think that is the case. If this was true then I highly doubt we would be sitting where we are now with very little recognition. But I hope you are correct cause then I will be a rich man in 6 months. I'm not a doctor and I don't pretend to be so human or animal biology is not something I can comment on. But good luck and I hope you are correct. We shall see very soon.
I agree fully with the potential but I believe you need to keep things in perspective. First this is pre-clinical studies in animal models. Human efficacy is a whole new ball game when it comes to clinical trials. I can point out several companies who released amazing pre-clinical data yet failed in human trials. It happens more often than not. But yes if and this is a big IF the trial is an success then WOW! Anavex is taking an approach that all others seem to not be taking in a cure for Alzheimers and epilepsy. But I really hope they will succeed with this trial and prove to all big pharma that we have the key to a cure for the most unmet medical need out there. Also I received an email to the patent issue that has been brought up on this board. I can post if needed but the email discloses all the patents and applications Anavex has on file with United States Patent Office.
how is your ass? Sorry but when I read that I immediately starting laughing my ass off! Your average in where? I'm not seeing profits until .43 so I have a long way to go. ATHX last week and this week well AVXL! Oh you have to love this shit!
Jbem777 put it to bed bro. Anyways whats your take on this recent decent into AVXL? Sector driven decline or just a pullback from a run? What's your take?
How many patients do you suspect will be enrolled when its all said and done? Cause I'm just trying to figure out the cost of all this. I know Keytruda is roughly 12,500 a month per patient but the costs that OncoSec will incur remains unanswered. Also will UCSF incur any expenses and if so what do they get out of the deal if the therapy is approved? This is all really interesting stuff.
With this being an investigator sponsored trial how is the approval process different vs. a traditional clinical trial? I'm trying to drum up info but its been quite difficult and I put in a call to UCSF Medical Center to assist but nothing yet?
Well said Fur. I know I don't contribute as much to this board as I use to due to workload, but I'm always checking in on posts. Thanks all for the extraordinary DD. You know who you are!!
I don't know about that. At the end Punit says about securing PD-1 or anti-PD-1 and will be doing so with a partner
Fur he has stated that before about the 2B trial being a registration trial cause that's where Im pulling it from. Anyways nothing bad all good can't wait to see what's in store. We are here boys!
Unless the FDA said "no" baby?
I thought the 2B trial was a registration trial?
2 have completed enrollment. Yes finally MCC!
Amen brother!
I believe tomorrow's conference will be very telling. I'm really looking forward to it!
Well I can't say I didn't see this coming. To be honest we do this to ourselves. We hype up each and every event hoping for news release and when it doesn't guess what it plummets. Not calling todays drop a plummet. I'm gonna go out on a limb here and say this is the most visited, most important message board that speaks on OncoSec. So we are partly responsible for the trading action. My suggestion is just sit back and chill cause it will happen when we least expect it.
Actually after reading into the PR more it looks to be for new novel approaches and to better develop electroporation.
Or this could be to assist with our new indication?
Sal here is my concern with this. I don't even know if this is possible, but with this grant I'm thinking that now our phase IIb trial will be not with a major pharma but with Old Dominion. It will be a investigator sponsored phase IIb trial. For some reason I feel that this might be why we received the grant? Anyone have thoughts?
Agree I don't think data will be bad however I wanted to rule it out by going over the science hoping to get an answer. I just don't know how that works? Also if they are sitting on data which I think is unlikely I would love to know there reasoning for that?
I'm not a science guru so hopefully someone here can help me. The primary measure of success for MCC is simply an 2 fold increase in IL-12. With secondary endpoints in safety and long-term survival. How could the interim data not be good if simply all is needed is a uptake of IL-12 when in fact that is what we are giving the patient? How does this all work?
According to IR's most recent email to me this morning milestones planned for 2014 are still on track to be met. As for Acorn I'm still playing phone tag with Kelly. I plan to update the board on our conversation as soon as I reach him.